Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study

Penny A. Asbell¹, Heleen H. DeCory²*

¹ Icahn School of Medicine at Mount Sinai, New York, New York, United States of America, ² Bausch + Lomb, Rochester, New York, United States of America

* heleen.decory@bausch.com

Abstract

The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study evaluates in vitro antibiotic resistance among *Staphylococcus aureus*, coagulase-negative staphylococci (CoNS), *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, and *Haemophilus influenzae* isolates from ocular infections. Here we report resistance rates and trends among conjunctival-sourced ocular isolates collected across the US from 2009 through 2016. A total of 1198 conjunctival isolates (483 *S. aureus*, 305 CoNS, 208 *H. influenzae*, 118 *S. pneumoniae*, and 84 *P. aeruginosa*) were collected from patients with presumed bacterial conjunctivitis from 57 sites across 40 states. A large proportion of staphylococci demonstrated resistance to oxacillin and azithromycin, while resistance was low against the majority of antibiotics tested for *S. pneumoniae*, *P. aeruginosa*, and *H. influenzae*. Multidrug resistance (≥3 antibiotic classes) was found in 30.2% of *S. aureus* and 39.0% of CoNS isolates, and methicillin resistance more than doubled the rate of multi-drug resistance (methicillin-resistant *S. aureus* [MRSA], 76.5%; methicillin-resistant CoNS isolates, 72.8%). There was a pattern of increasing mean percent resistance with increasing age by decade of life among *S. aureus*, MRSA, and CoNS (*P* < 0.038). Over the eight-year study period, there were small yet significant decreases in resistance rates among *S. aureus* to azithromycin, ciprofloxacin, tobramycin, trimethoprim, and oxacillin (*P* < 0.003), and among CoNS and *P. aeruginosa* (both *P* < 0.05) to ciprofloxacin. These data indicate that antibiotic resistance is high, but did not increase, among conjunctival-sourced isolates collected in the US from 2009 through 2016. For certain antibiotic/pathogen combinations, there was a trend of decreased resistance, including a decrease in oxacillin resistance among *S. aureus*.
Introduction

Conjunctivitis is a common ocular infection affecting all age groups [1]. While a viral etiology is responsible for the majority of adult cases, bacterial conjunctivitis is the second most common cause in adults and may be the primary cause in children [2,3]. Causative bacterial agents among adults are most frequently staphylococcal species, followed by *Streptococcus pneumoniae* and *Haemophilus influenzae*, with *Pseudomonas aeruginosa* common in contact lens wearers [4–6]. In children, *H. influenzae* is the most common pathogen, followed by *S. pneumoniae*, *Staphylococcus aureus*, and *Staphylococcus epidermidis* [7–10].

While bacterial conjunctivitis is generally self-limiting, treatment with topical antibiotics is associated with earlier clinical and microbiological remission, as well as decreased discomfort and morbidity [1,9,11,12]. In children, treatment is especially important as many US state departments of health require that children be kept home from day care/school until they are asymptomatic or under treatment [13]. Antibiotic therapy is typically initiated empirically, with guidelines recommending cultures only in severe, chronic, recurrent, or treatment-unresponsive cases [1].

Since the introduction of antibiotics, bacterial resistance has continued to pose an ongoing problem across infectious diseases, and ocular infection pathogens are no exception [4,14–25]. The presence of antibiotic resistance among ocular pathogens is of concern, as it complicates the choice of antibiotic and may lead to treatment failure [26–30]. However, few surveillance studies have specifically focused on susceptibility patterns among ocular pathogens, and most have been single-center studies [4,20,23,26,31].

To date, there have been only two nationwide, multi-center prospective surveillance studies, one of which is currently active. The Ocular Tracking Resistance in US Today (TRUST) study which evaluated ocular pathogens collected from 2005 through 2008 reported in vitro resistance among *S. aureus*, *H. influenzae*, and *S. pneumoniae* isolates to a number of commonly used topical antibiotics, with in vitro methicillin resistance increasing significantly among *S. aureus* and CoNS over the three-year study period [32–34]. The Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study, initiated in January 2009, is the only surveillance initiative specific to ocular pathogens currently ongoing. Comprehensive five- and seven-year cumulative findings of the ARMOR study have been published [15,34]. Herein, we report in vitro antibiotic resistance profiles and trends for 1198 bacterial isolates obtained from patients with presumed bacterial conjunctivitis over 8 years of the ARMOR surveillance study.

Methods

Isolates of *S. aureus*, CoNS, *S. pneumoniae*, *H. influenzae*, and *P. aeruginosa* cultured from eye infections were submitted by participating US sites as part of the ARMOR surveillance study [15,16,34]. From 2009–2013, each participating site was invited to submit up to 65 ocular isolates per collection year, including no more than 20 *S. aureus*, 20 CoNS, 5 *S. pneumoniae*, 5 *H. influenzae*, and 15 *P. aeruginosa*; whereas from 2014–2016, participating sites were invited to submit a maximum of 50 isolates per collection year of *S. aureus*, CoNS, *S. pneumoniae*, *H. influenzae*, and *P. aeruginosa*, with no more than 12 isolates of any given species. The central laboratory in ARMOR obtained pure subcultures of bacterial isolates from each of the 87 participating clinical sites from 2009–2016; not all sites submitted samples throughout all 8 years. The current study reports antibiotic resistance rates and trends among ocular isolates collected from the conjunctiva from January 1, 2009, through December 31, 2016.

There were no human participants involved in ARMOR, or specimens or tissue samples actively taken as part of ARMOR. Because this was a laboratory study, institutional review
board approval was left to the discretion of participating sites, but not required because no patient identifying information was provided with isolates. The present analyses were limited to isolates characterized by participating centers as originating from the conjunctiva.

Species confirmation and antibiotic resistance profile determination for each isolate were performed at a central laboratory (Eurofins Medinet, Chantilly, VA [2009–2013]; IHMA Inc, Schaumburg, IL [2014–2016]). Minimum inhibitory concentrations (MIC) were determined by broth microdilution according to the Clinical and Laboratory Standards Institute (CLSI) methods using frozen antimicrobial microtiter panels [35–37]. Each isolate was tested against antibiotics from 10 different classes as appropriate based on species. Antibiotics included the fluoroquinolones (ciprofloxacin, moxifloxacin, gatifloxacin, besifloxacin, levofloxacin, and ofloxacin), macrolides (azithromycin), aminoglycosides (tobramycin), lincosamides (clindamycin), penicillins (oxacillin and/or penicillin), dihydrofolate reductase inhibitors (trimethoprim), polypeptides (polymyxin B), amphenicols (chloramphenicol), tetracyclines (tetracycline) and glycopeptides (vancomycin). Not all antibiotic classes were tested in each of the 8 years of the study period.

CLSI interpretive criteria [38–45], which are based on data from systemic infections, were used to interpret MICs as susceptible, intermediate, or resistant for each species/antibiotic combination (when available). Isolates were reported as resistant if they classified as either intermediate or resistant during MIC testing. For staphylococci isolates, susceptibility to oxacillin was used to categorize isolates as methicillin-resistant (MR) or methicillin-susceptible (MS). Susceptibility of *S. pneumoniae* isolates to penicillin was based on the breakpoint for oral penicillin. Resistance to three or more classes of antibiotics was defined as multidrug resistance.

For analysis by age of the source patient, isolates were categorized into age groups by decade of life. For analysis by geography, isolates were categorized into four regions based on state in which the participating center was located: Western US (AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY), Midwestern US (IA, IL, IN, KS, KY, MI, MN, MO, ND, NE, OH, SD, WI), Southern US (AL, AR, FL, GA, LA, MD, MS, NC, OK, SC, TN, TX, VA, WA, WV) and Northeastern US (CT, DE, MA, ME, NH, NJ, NY, PA, RI, VT).

To determine if resistance among conjunctiva isolates differed across age groups or geographic location, a one-way analysis of variance (ANOVA) was conducted. Because not all antibiotic classes were tested in each of the 8 years of the study period, the ANOVA utilized the means of the percentage of drug classes to which each isolate of a species/species group was resistant. Results of significance were then subjected to further testing using Tukey’s Honestly Significant Differences (HSD) All-Pairwise Comparisons Test [46], which used the *P*<0.1 criterion for statistical significance.

Where indicated, differences among staphylococcal isolates based on MR status were determined using a Chi-Square Test followed by a multiple comparisons test for proportions. The Cochran-Armitage test for linear trends in a proportion [47] was used to evaluate changes in resistance rates over time. Statistical significance was defined as a *P* value <0.05 unless otherwise indicated. Statistical testing was performed using Statistix 10 (Analytical Software, Tallahassee, FL) or GraphPad Prism 5.01 (San Diego, CA).

**Results**

A total of 1198 isolates (483 *S. aureus*, 305 CoNS, 208 *H. influenzae*, 118 *S. pneumoniae*, and 84 *P. aeruginosa*) from the conjunctiva were collected from 57 participating centers across 40 states in the US. The majority of isolates came from the Midwest region (n = 499; 41.7%), followed by the Northeast (n = 286; 23.9%), West (n = 280; 23.4%), and South (n = 133; 11.1%).
An equal percentage of isolates were collected from male \( n = 558; 46.6\% \) and female \( n = 560; 46.7\% \) patients (unknown for 80 \( 6.7\% \) isolates). One-quarter (24.6\%) of the conjunctival-sourced isolates were obtained from patients aged 0–9 years (Fig 1).

### In vitro antibiotic resistance rates

**Table 1** presents MIC\(_{90}\) (the MIC required to inhibit the growth of 90% of isolates) and antibiotic resistance profiles for the *S. aureus*, CoNS, *S. pneumoniae*, and *P. aeruginosa* isolates collected from presumed conjunctivitis cases.

Of *S. aureus* isolates, cumulative in vitro resistance to azithromycin, ciprofloxacin, tobramycin, and oxacillin (MR *S. aureus* [MRSA]) was 56.7%, 33.6%, 19.1%, and 31.7%, respectively. Resistance to chloramphenicol (5.8%) and trimethoprim (5.8%) was low. Compared to MSS *S. aureus* (MSSA), MRSA strains demonstrated greater in vitro resistance to azithromycin (93.5% vs 39.7%), tobramycin (49.7% vs 4.9%), and the fluoroquinolones ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin (75.6%–78.6% vs 10.9%–13.0%). MIC\(_{90}\)s were lower for newer fluoroquinolones (besifloxacin, moxifloxacin, gatifloxacin, and levofloxacin) as compared to older fluoroquinolones (ofloxacin, ciprofloxacin, and levofloxacin). The lowest MIC\(_{90}\) among all tested antibiotics were for besifloxacin (MSSA, 0.25 \( \mu \)g/mL; MRSA, 4 \( \mu \)g/mL) and vancomycin (MSSA and MRSA, both 1 \( \mu \)g/mL).

Among CoNS isolates, cumulative in vitro resistance was greatest to azithromycin (63.3%) and oxacillin (MRCoNS; 48.2%), followed by ciprofloxacin (30.5%), trimethoprim (28.1%), and tobramycin (16.1%). Resistance to chloramphenicol was low (1.9%). As observed with MRSA, higher rates of resistance were found among MRCoNS isolates when compared to MSCoNS. As observed with *S. aureus*, MIC\(_{90}\) for both MSCoNS and MRCoNS were lower with newer fluoroquinolones as compared with older fluoroquinolones, and besifloxacin exhibited the lowest MIC\(_{90}\) (MSCoNS, 0.25 \( \mu \)g/mL; MRCoNS, 2 \( \mu \)g/mL).

In vitro resistance among *S. pneumoniae* isolates was low for the majority of antibiotics tested, and all isolates were susceptible to tested fluoroquinolones (Table 1). However, resistance to azithromycin (31.4%), tetracycline (15.4%), imipenem (8.8%), and penicillin (29.7%) was noted. Besifloxacin demonstrated the lowest MIC\(_{90}\) of all tested antibiotics (0.06 \( \mu \)g/mL).

The *P. aeruginosa* isolates demonstrated high rates of in vitro susceptibility to tested antibiotics, with the highest resistance rates being 14.6% for imipenem, 8.5% for gatifloxacin, 8.5% for oxacillin, and 8.3% for ciprofloxacin. MIC\(_{90}\)s were lowest for ciprofloxacin, gatifloxacin, levofloxacin, and tobramycin (1 \( \mu \)g/mL for all).

Among *H. influenzae* isolates, in vitro resistance was observed in only 4 isolates (2 –azithromycin; 1 –tetracycline/chloramphenicol; 1 –tetracycline). All other isolates were susceptible to all antibiotics tested. For the fluoroquinolones tested, MIC\(_{90}\)s for besifloxacin, moxifloxacin, and oxacillin were each 0.03 \( \mu \)g/mL and 0.015 \( \mu \)g/mL for ciprofloxacin, gatifloxacin, and levofloxacin. Other MIC\(_{90}\) included 2 \( \mu \)g/mL for azithromycin, 1 \( \mu \)g/mL for chloramphenicol, and 0.5 \( \mu \)g/mL for tetracycline.

Multidrug in vitro resistance (resistance to ≥3 classes of antibiotics) was found in 30.2% of *S. aureus* and 39.0% of CoNS isolates (Fig 2). These percentages increased to 76.5% and 72.8% when examining only MRSA and MRCoNS, respectively. In contrast, MS staphylococcal isolates were less likely to be multidrug-resistant (8.8% of MSSA and 7.6% of MSCoNS isolates).

### In vitro resistance rates by patient age

As shown in Fig 3, there was a general pattern of increasing mean percentage in vitro resistance with increasing age by decade of life among both *S. aureus* \( (P<0.0001) \) and CoNS \( (P = 0.0378) \), as well as for MRSA \( (P = 0.0001) \). For *S. aureus* isolates, pairwise differences were...
found between isolates from patients aged 0–9 years compared to those aged ≥70 years, those aged 50–59 years compared to those aged ≥80, and for all patients <90 compared to those ≥90. For CoNS isolates, pairwise differences were found between those from patients aged 30–39 years when compared to those from patients aged 80–89 years. Further, among the subset of MRSA isolates specifically, pairwise differences in mean percentage of resistance were found between isolates from patients aged 0–9 years compared to those aged ≥80 years, and between isolates from patients aged 20–29 years compared to those aged ≥70 years. There was no evidence of an association between age by decade of life and mean percentage of resistance among MRCoNS ($P = 0.1341$), *S. pneumoniae* ($P = 0.1760$), *P. aeruginosa* ($P = 0.5308$), or *H. influenzae* ($P = 0.9846$).

In vitro oxacillin resistance (Fig 4) also differed by age group for *S. aureus* ($P<0.0001$), with lower resistance observed among isolates from patients aged 0–9 years compared to those aged 20–29 and ≥60 years, and higher resistance in isolates from patients aged ≥90 years compared to those aged 40–59 years; no differences in oxacillin resistance by age were observed for CoNS ($P = 0.4050$).

### In vitro resistance rates by geography

When analyzing in vitro resistance rates for isolates by geographic region of origin, significant differences were found across regions in mean percentage of resistance for *S. aureus* ($P = 0.0002$) and *S. pneumoniae* ($P = 0.0003$). Mean (standard error, SE) *S. aureus* resistance was highest in the Southern (30.4% [2.6]) and Northeastern (24.1% [2.2]) regions and lowest in the Midwestern (18.6% [1.7]) and Western (17.0% [2.1]) regions. Mean (SE) percentage of resistance in *S. pneumoniae* was highest in the Midwestern region (31.2% [3.4]) and lowest in
Table 1. Minimum inhibitory concentrations and resistance profiles for conjunctival *S. aureus*, coagulase-negative staphylococci, *S. pneumoniae*, and *P. aeruginosa* from ARMOR 2009–2016.

| Organism(s) | Antibiotic | N° | MIC₉₀ (μg/mL) | Susceptible | Intermediate | Resistant |
|-------------|------------|----|--------------|-------------|--------------|-----------|
|             |            |    |              | %           | %            | %         |
| *S. aureus* |            |    |              |             |              |           |
|             | Ofloxacin  | (All) 414 | >8            | 66.7        | 0.72         | 32.6      |
|             |            | (MSSA) 288 | 8             | 86.5        | 1.0          | 12.5      |
|             |            | (MRSA) 126 | 64            | 21.4        | 0.0          | 78.6      |
|             | Ciprofloxacin | (All) 483 | 128           | 66.5        | 1.0          | 32.5      |
|             |            | (MSSA) 330 | 8             | 87.0        | 1.2          | 11.8      |
|             |            | (MRSA) 153 | 256           | 22.2        | 0.7          | 77.1      |
|             | Levofloxacin | (All) 414 | 32            | 67.6        | 1.9          | 30.4      |
|             |            | (MSSA) 288 | 4             | 87.9        | 1.4          | 10.8      |
|             |            | (MRSA) 126 | 128           | 21.4        | 3.2          | 75.4      |
|             | Gatifloxacin | (All) 414 | 8             | 67.4        | 3.4          | 29.2      |
|             |            | (MSSA) 288 | 2             | 87.5        | 2.4          | 10.1      |
|             |            | (MRSA) 126 | 16            | 21.4        | 5.6          | 73.0      |
|             | Moxifloxacin | (All) 483 | 8             | 68.3        | 6.0          | 25.7      |
|             |            | (MSSA) 330 | 1             | 89.1        | 3.3          | 7.6       |
|             |            | (MRSA) 153 | 16            | 23.5        | 11.8         | 64.7      |
|             | Besifloxacin | (All) 483 | 1             | na          | na           | na        |
|             |            | (MSSA) 330 | 0.25          | na          | na           | na        |
|             |            | (MRSA) 153 | 4             | na          | na           | na        |
|             | Azithromycin | (All) 483 | >512          | 43.3        | 0.4          | 56.3      |
|             |            | (MSSA) 330 | >512          | 60.3        | 0.6          | 39.1      |
|             |            | (MRSA) 153 | >512          | 6.5         | 0.0          | 93.5      |
|             | Clindamycin | (All) 483 | >2            | 84.7        | 1.2          | 14.1      |
|             |            | (MSSA) 330 | 0.25          | 92.4        | 1.5          | 6.1       |
|             |            | (MRSA) 153 | >16           | 68.0        | 0.7          | 31.4      |
|             | Chloramphenicol | (All) 414 | 8             | 94.2        | 5.1          | 0.7       |
|             |            | (MSSA) 288 | 8             | 96.2        | 3.1          | 0.7       |
|             |            | (MRSA) 126 | 16            | 89.7        | 9.5          | 0.8       |
|             | Tobramycin | (All) 483 | 128           | 81.0        | 2.3          | 16.8      |
|             |            | (MSSA) 330 | 1             | 95.2        | 0.3          | 4.6       |
|             |            | (MRSA) 153 | 256           | 50.3        | 6.5          | 43.1      |
|             | Trimethoprim | (All) 414 | 4             | 94.2        | 0.0          | 5.8       |
|             |            | (MSSA) 288 | 4             | 96.2        | 0.0          | 3.8       |
|             |            | (MRSA) 126 | >128          | 89.7        | 0.0          | 10.3      |
|             | Vancomycin | (All) 483 | 1             | 100         | 0.0          | 0.0       |
|             |            | (MSSA) 330 | 1             | 100         | 0.0          | 0.0       |
|             |            | (MRSA) 153 | 1             | 100         | 0.0          | 0.0       |

| Coagulase-Negative Staphylococci |           |    |              | %           | %            | %         |
|----------------------------------|-----------|----|--------------|-------------|--------------|-----------|
| (All) 260                        |           |    |              |             |              |           |
| Ofloxacin                        | (MSSCoNS) 137 | 1 | 90.5        | 0.0          | 9.5         |
|                                  | (MRCoNS) 123 | 32 | 50.4        | 0.0          | 49.6        |
| Ciprofloxacin                    | (All) 305 | 64 | 69.5        | 2.0          | 28.5        |
|                                  | (MSSCoNS) 158 | 4 | 89.2        | 0.6          | 10.1        |
|                                  | (MRCoNS) 147 | 64 | 48.3        | 3.4          | 48.3        |

(Continued)
| Organism(s)          | Antibiotic         | No. | MIC₉₀ (µg/mL) | Susceptible | Intermediate | Resistant |
|---------------------|--------------------|-----|--------------|-------------|--------------|-----------|
|                     |                    |     |              | %           | %            | %         |
| Levofloxacin        | (All) 260          | 16  | 71.5         | 3.5         | 25.0         |           |
|                     | (MCoNS) 137        | 0.5 | 90.5         | 0.7         | 8.8          |           |
|                     | (MRCoNS) 123       | 128 | 50.4         | 6.5         | 43.1         |           |
| Gatifloxacin        | (All) 260          | 4   | 71.5         | 4.6         | 23.9         |           |
|                     | (MCoNS) 137        | 0.5 | 90.5         | 2.2         | 7.3          |           |
|                     | (MRCoNS) 123       | 32  | 50.4         | 7.3         | 42.3         |           |
| Moxifloxacin        | (All) 305          | 8   | 72.8         | 4.3         | 23.0         |           |
|                     | (MCoNS) 158        | 1   | 89.9         | 2.5         | 7.6          |           |
|                     | (MRCoNS) 147       | 32  | 54.4         | 6.1         | 39.5         |           |
| Besifloxacin        | (All) 305          | 1   | na           | na          | na           |           |
|                     | (MCoNS) 158        | 0.25| na           | na          | na           |           |
|                     | (MRCoNS) 147       | 2   | na           | na          | na           |           |
| Azithromycin        | (All) 305          | >512| 36.7         | 0.0         | 63.3         |           |
|                     | (MCoNS) 158        | >512| 53.2         | 0.0         | 46.8         |           |
|                     | (MRCoNS) 147       | >512| 19.1         | 0.0         | 81.0         |           |
| Clindamycin         | (All) 305          | >64 | 68.9         | 5.6         | 25.6         |           |
|                     | (MCoNS) 158        | 16  | 79.8         | 7.0         | 13.3         |           |
|                     | (MRCoNS) 147       | >64 | 57.1         | 4.1         | 38.8         |           |
| Chloramphenicol     | (All) 260          | 8   | 98.1         | 0.8         | 1.2          |           |
|                     | (MCoNS) 137        | 4   | 97.8         | 0.7         | 1.5          |           |
|                     | (MRCoNS) 123       | 8   | 98.4         | 0.8         | 0.8          |           |
| Tobramycin          | (All) 305          | 8   | 83.9         | 6.6         | 9.5          |           |
|                     | (MCoNS) 158        | 4   | 94.3         | 3.8         | 1.9          |           |
|                     | (MRCoNS) 147       | 32  | 72.8         | 9.5         | 17.7         |           |
| Trimethoprim        | (All) 260          | 256 | 71.9         | 0.0         | 28.1         |           |
|                     | (MCoNS) 137        | >128| 83.9         | 0.0         | 16.1         |           |
|                     | (MRCoNS) 123       | >256| 58.5         | 0.0         | 41.5         |           |
| Vancomycin          | (All) 305          | 2   | 100          | 0.0         | 0.0          |           |
|                     | (MCoNS) 158        | 2   | 100          | 0.0         | 0.0          |           |
|                     | (MRCoNS) 147       | 2   | 100          | 0.0         | 0.0          |           |

**S. pneumoniae**

| Antibiotic | No. | MIC₉₀ (µg/mL) | Susceptible | Intermediate | Resistant |
|------------|-----|--------------|-------------|--------------|-----------|
| Ofloxacin  | 96  | 2            | 100         | 0.0          | 0.0       |
| Ciprofloxacin | 118 | 1            | na          | na           | na        |
| Levofloxacin | 96  | 1            | 100         | 0.0          | 0.0       |
| Gatifloxacin | 96  | 0.25         | 100         | 0.0          | 0.0       |
| Moxifloxacin | 118 | 0.25         | 100         | 0.0          | 0.0       |
| Besifloxacin | 118 | 0.06         | na          | na           | na        |
| Azithromycin | 118 | >128         | 68.6        | 0.0          | 31.4      |
| Chloramphenicol | 118 | 4            | 98.3        | 0.0          | 1.7       |
| Ceftriaxone | 79  | 1            | 94.9        | 5.1          | 0.0       |
| Imipenem   | 57  | 0.12         | 91.2        | 5.3          | 3.5       |
| Penicillin  | 118 | 1            | 70.3        | 20.3         | 9.3       |
| Tetracycline | 39  | >4           | 84.6        | 0            | 15.4      |

**P. aeruginosa**

| Antibiotic | No. | MIC₉₀ (µg/mL) | Susceptible | Intermediate | Resistant |
|------------|-----|--------------|-------------|--------------|-----------|
| Ofloxacin  | 71  | 2            | 91.6        | 1.4          | 7.0       |
| Ciprofloxacin | 84  | 1            | 91.7        | 1.2          | 7.1       |

(Continued)
the Northeastern (14.3% [5.0]), Western (9.5% [4.6]), and Southern (6.5% [8.3]) regions.

There was no evidence for regional differences among mean percentage of resistance for MRSA, CoNS, MRCoNS, *P. aeruginosa*, or *H. influenzae*.

Similarly, a significant difference was noted with respect to oxacillin resistance specifically between regions for *S. aureus* (*P* = 0.0002). *S. aureus* resistance to oxacillin was 22.2%, 26.6%, 38.1%, and 48.7% in the Western, Midwestern, Northeastern, and Southern regions respectively, with significance differences between the Midwestern and Southern regions, and between the Western and both Northeastern and Southern regions. There was no evidence of differences across regions regarding resistance to oxacillin for CoNS.

### In vitro resistance rates over time

Over the eight-year study period, there were small yet significant decreases in in vitro resistance rates for *S. aureus* to azithromycin (*P* = 0.0028), ciprofloxacin (*P*<0.0001), tobramycin (*P* = 0.0001), trimethoprim (*P* = 0.0077), and oxacillin (*P*<0.0001) (Fig 5). For MRSA isolates, a decrease in resistance from 2009 to 2016 was found only to trimethoprim (*P* = 0.0478). There were also small yet significant decreases in in vitro resistance to ciprofloxacin among CoNS (*P* = 0.0125) and *P. aeruginosa* (*P* = 0.0249) isolates. Oxacillin resistance did not change among CoNS (*P* = 0.3298), nor were there significant changes in resistance rates for MRCoNS or *S. pneumoniae* to any of the tested antibiotics over the eight-year study period.

### Discussion

Initiated in 2009, the ARMOR study is the only prospective, ongoing, multicenter, nationwide surveillance study designed to monitor antibiotic resistance among *S. aureus*, CoNS, *S. pneumoniae*, *H. influenzae*, and *P. aeruginosa* isolates from ocular infections. The current analysis of almost 1200 isolates obtained from 2009 through 2016 sourced from the conjunctiva and presumed causative in bacterial conjunctivitis is the largest dataset on such isolates to our knowledge. Findings from the current analysis indicate substantial levels of in vitro resistance to commonly used antibiotics, particularly among staphylococci species, almost half of which demonstrated resistance to oxacillin. Methicillin resistant staphylococci exhibited increased
Resistance to other classes of antibiotics compared to methicillin sensitive strains—as attested to by the analysis of multidrug resistance and mean percentage of resistance. Conversely, resistance among *S. pneumoniae* isolates was notable only for azithromycin and penicillin, while both *P. aeruginosa* and *H. influenzae* isolates appeared highly susceptible to all tested antibiotics.

While there are little published data on antibiotic resistance among ocular pathogens, and none specific to common conjunctival isolates on a national level, the findings are generally consistent with previously reported single-center or regional studies in the US that evaluated susceptibility patterns of conjunctival isolates. An analysis of 12,134 presumed bacterial conjunctivitis isolates from the northeastern US [4] found patterns of increased in vitro resistance...
to older as opposed to newer generation fluoroquinolones among *S. aureus*, similar to the current ARMOR analysis; 30.1% of *S. aureus* isolates in that study were oxacillin-resistant (MRSA) [4]. Other studies that reported resistance data for conjunctival isolates obtained from clinical situations other than conjunctivitis have noted high rates of in vitro oxacillin resistance similar to that observed in the ARMOR data. In a Stanford University (California) study of isolates obtained prior to intravitreal injection, 47% of CoNS isolates were resistant to oxacillin [48]; a similar prevalence of oxacillin resistance (46.6%) was found among CoNS isolates obtained from cataract surgery patients in the midwestern US [49].

Of note, compared to the 7-year ARMOR results [34], which was inclusive of all ocular isolates and not limited to those obtained from the conjunctiva only, there was little variation in overall cumulative in vitro resistance observed. These findings indicate that bacterial resistance
rates among the subset of isolates collected specifically from the conjunctiva reflect those observed in the larger and broader ARMOR dataset and suggests antibiotic resistance may not differ much by etiology although additional study is needed. The majority of MIC\textsubscript{90} patterns also paralleled previous ARMOR reports \cite{15,16,34}, with all tested staphylococcal isolates remaining susceptible to vancomycin. Lower MICs were found when testing isolates against newer fluoroquinolones as opposed to older fluoroquinolones, especially among the staphylococci isolates. The only notable difference between the comprehensive 7-year ARMOR data and the current conjunctival data was found among MRSA for trimethoprim (MIC\textsubscript{90} of 2 vs MIC\textsubscript{90} > 128, respectively). The reason for this difference is unclear but likely due to the relative impact of a small number (10.3\%) of MRSA isolates with high in vitro resistance to trimethoprim to the current MRSA data set as opposed to the larger comprehensive 7-year MRSA data set (4.5-fold larger). For gram-positive isolates, the antibiotic with the lowest MIC\textsubscript{90} in both this study and the 7-year data set \cite{34} was besifloxacin, a chloro-fluoroquinolone developed for topical ophthalmic use only \cite{50–55}. There were no changes over time in besifloxacin MIC\textsubscript{90} in either data set, attesting to its balanced inhibition of both DNA gyrase and topoisomerase IV, and low in vitro mutation frequency in mutant selection experiments \cite{56}.

When analyzing resistance trends by age, an overall increase in antibiotic resistance with greater age was present among staphylococci, consistent with prior reports \cite{15,16,57}. Older
patients are more likely than younger patients to be exposed to environments (e.g., nursing homes, hospitals) in which close living conditions, coupled with the presence of high levels of antibiotic-resistant pathogens, allow for rapid spread of resistant infections. Analysis by geographic region revealed significant findings only for *S. aureus*, in which there was little variation from previous ARMOR findings [15]. In general, mean percentage resistance rates, as well as oxacillin resistance, among *S. aureus* isolates appeared to remain high in the South and low in the West. While the reasons for this geographic disparity are unknown, it could be due to differences in regional prescribing patterns and stewardship practices.
Overall, the decreasing trends for in vitro resistance of conjunctival-sourced isolates over the 8-year study period are encouraging. All staphylococcal and P. aeruginosa isolates demonstrated significant decreases in resistance to ciprofloxacin, and S. aureus isolates also demonstrated significant decreases in resistance to oxacillin, azithromycin, and tobramycin. These data generally paralleled the comprehensive 7-year analysis trends [34], although the previously reported small increases in resistance to tobramycin among MRCoNS and to azithromycin among S. pneumoniae were not duplicated in the current analysis. Oxacillin resistance among CoNS did not increase in either study. The noted decreases in resistance to some antibiotics may reflect more judicious antibiotic use and an improved awareness of measures aimed to combat the growing concern of antibiotic resistance.

While the ARMOR surveillance study was not designed to correlate in vitro susceptibility data with clinical treatment, nor does it collect treatment outcome data, associations between in vitro susceptibility and clinical outcomes have been suggested elsewhere. A retrospective, cross-sectional review of pediatric ocular and peri-ocular infection cases (40% conjunctivitis) with culture-positive MRSA isolates in a northern California pediatric population showed high in vitro resistance to multiple antibiotics with many topical treatment failures [26]. Wilhelmus et al [27] prospectively studied the clinical impact of MICs on clinical response of culture-confirmed bacterial keratitis in patients treated with ciprofloxacin; findings indicated a 43% reduction in improvement and 29% reduction in cure rate among cases in which the pathogen MIC for ciprofloxacin was >1 \( \mu \)g/mL compared to infections caused by organisms with greater in vitro sensitivity (ie, lower MIC).

The current study is subject to several limitations. All samples were obtained within the US, thereby limiting the global generalizability of the data. Although community hospitals and reference laboratories were included as participating centers, the majority of isolates in ARMOR are obtained from hospitals or referral centers and resistance rates therefore may not reflect antibiotic resistance rates in community practices where cultures are seldom taken in cases of suspected bacterial conjunctivitis. For this reason and given ARMOR investigators are instructed only to submit isolates for cases deemed clinically significant, there is likely sampling bias towards more severe conjunctivitis cases. Another limitation is the choice of antibiotics tested; alternate antibiotics within a drug class may have been selected for susceptibility testing. As well, systemic breakpoints were used to interpret MIC data for ocular isolates, and for some antibiotics tested (eg, besifloxacin) there were no established breakpoints to help interpret MIC data. The value of systemic breakpoints for topical ocular treatments remains unclear, owing to the unique pharmacokinetic consequences of ocular administration. On one hand, topical application allows for much higher immediate drug concentrations at the infection site than would be achievable with systemic drug administration, potentially leading to over-reporting of resistance when utilizing systemic breakpoints [58]. On the other hand, topically applied antibiotics are subjected to rapid dilution and removal through blinking and tear turnover, phenomena which limit residence time on the surface of the eye. Yet, as mentioned, some studies applying systemic breakpoints in ocular infections have correlated in vitro resistance with treatment failures [26–30]. Thus, in the absence of topical breakpoints, systemic breakpoints remain useful in determining the antibiotic resistance patterns of ocular isolates and relative susceptibilities to various antibiotics.

Conclusions

Data from the nationwide ARMOR surveillance study indicate that antibiotic in vitro resistance rates did not increase among ocular isolates originating from the conjunctiva collected from 2009 through 2016. Instead, there was a favorable trend of decreased resistance for
certain antibiotic/pathogen combinations, including a decrease in oxacillin resistance among
*S. aureus*. Despite these positive findings, antibiotic resistance and multidrug resistance remain
high among conjunctival isolates, particularly among *S. aureus* and CoNS pathogens. Due to
the likely sampling bias towards more severe cases of bacterial conjunctivitis, these resistance
data should be interpreted with caution.

**Supporting information**

**S1 Text. Age analysis.** Statistical analyses of resistance among isolates from the conjunctiva by
patient age.

(DOCX)

**S2 Text. Geographic analysis.** Statistical analyses of resistance among isolates from the con-
junctiva by geographic region.

(DOCX)

**S1 Table. Longitudinal trend data.** Resistance among isolates from the conjunctiva by antibi-
otic class over the 8-year study period.

(XLS)

**S2 Table. Multidrug resistance data.** Multidrug resistance among staphylococcal isolates
from the conjunctiva.

(XLS)

**Acknowledgments**

The authors acknowledge the writing assistance of Rachel Hathcock, RN of Churchill Commu-
nications, funded by Bausch & Lomb Incorporated.

**Author Contributions**

**Conceptualization:** Heleen H. DeCory.

**Data curation:** Penny A. Asbell, Heleen H. DeCory.

**Formal analysis:** Penny A. Asbell, Heleen H. DeCory.

**Funding acquisition:** Heleen H. DeCory.

**Investigation:** Heleen H. DeCory.

**Writing – review & editing:** Penny A. Asbell, Heleen H. DeCory.

**References**

1. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern®
   Guidelines. Conjunctivitis. San Francisco, CA: American Academy of Ophthalmology; 2013. Available
   at: https://www.aao.org/preferred-practice-pattern/conjunctivitis-PPP—2013. Accessed January 16,
   2017.

2. Azari AA, Barney NP. Conjunctivitis: A systematic review of diagnosis and treatment. JAMA. 2013; 310
   (16): 1721–1729. https://doi.org/10.1001/jama.2013.280318 PMID: 24150468

3. Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008; 86(1): 5–17. https://doi.org/10.1111/j.
   1600-0420.2007.01006.x PMID: 17970823

4. Adebayo A, Parikh JG, McCormick SA, Shah MK, Huerto RS, Yu G, et al. Shifting trends in in vitro anti-
biotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye
   and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011; 249(1): 111–119. https://doi.org/10.1007/
   s00417-010-1426-6 PMID: 20532549

5. Epling J. Bacterial conjunctivitis. BMJ Clin Evid. 2012; 2012:704.
6. Mueller JB, McStay CM. Ocular infection and inflammation. Emerg Med Clin N Am. 2008; 26:57–72.
7. Chen FV, Chang TC, Cavuoto KM. Patient demographic and microbiology trends in bacterial conjunctivitis in children. J AAPOS. 2018; 22(1): 66–67. https://doi.org/10.1016/j.aaapos.2017.08.008 PMID: 29247795
8. Patel PB, Diaz MCG, Bennett JE, Attia MW. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med. 2007; 14(1): 1–5. https://doi.org/10.1197/j.aem.2006.08.006 PMID: 17119185
9. Everitt HA, Little PS, Smith PWF. A randomized controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ. 2006; 333(7563): 321. https://doi.org/10.1136/bmj.38891.551088.7C PMID: 16847013
10. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: A post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Pediatr Drugs. 2010; 12 (2): 105–112.
11. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012; 9: CD001211.
12. Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clin Ther. 2011; 33(1): 13–26. https://doi.org/10.1016/j.clinthera.2010.12.004 PMID: 21397770
13. Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of state departments of health. J Pediatr Ophthalmol Strabismus. 2007; 44(2): 101–105. PMID: 17410961
14. Asbell PA, Sahm DF, Sheddlen A. Ocular TRUST 3: ongoing longitudinal surveillance of antimicrobial susceptibility in ocular isolates. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting; April 7, 2009; San Francisco, CA.
15. Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic resistance among ocular pathogens in the United States: Five-year results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. JAMA Ophthalmol. 2015; 133(12): 1445–1454. https://doi.org/10.1001/jamaophthalmol.2015.3888 PMID: 26502312
16. Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: Results from the Antibiotic Resistance Monitoring in Ocular micRooorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011; 152(4): 567–574. https://doi.org/10.1016/j.ajo.2011.03.010 PMID: 21652021
17. McDonald M, Blondeau JM. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg. 2010; 36 (9): 1588–1598. https://doi.org/10.1016/j.jcrs.2010.06.028 PMID: 20692574
18. Bertino JS Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol. 2009; 3: 507–521. PMID: 19789660
19. Holland EJ, McDonald MB, Parekh JG, Sheppard JD. Antibiotic resistance in acute postoperative endophthalmitis. Ophthalmology. 2014; 121(11 Suppl): S1–S9.
20. Ni N, Nam EM, Hammersmith KM, Nagra PK, Azari AA, Leiby BE, et al. Seasonal, geographic, and antimicrobial resistance patterns in microbial keratitis: 4-year experience in eastern Pennsylvania. Cornea. 2015; 34(3): 296–302. https://doi.org/10.1097/ICO.0000000000000352 PMID: 25603231
21. Sharma S. Antibiotic resistance in ocular bacterial pathogens. Indian J Med Microbiol. 2011; 29(3): 218–222. https://doi.org/10.4103/0255-0857.83903 PMID: 21860100
22. Gentile RC, Shukla S, Shah M, Ritterband DC, Engelbert M, Davis A, et al. Microbiological spectrum and antibiotic sensitivity in endophthalmitis: a 25-year review. Ophthalmology. 2014; 121(8): 1634–1642. https://doi.org/10.1016/j.ophtha.2014.02.001 PMID: 24702755
23. Chang VS, Dhaliwal DK, Raju L, Kowalski RP. Antibiotic resistance in the treatment of Staphylococcus aureus keratitis: a 20-Year Review. Cornea. 2015; 34(6): 698–703. https://doi.org/10.1097/ICO.0000000000000431 PMID: 25811722
24. Block SL, Hedrick J, Tyler R, Smith A, Findlay R, Keegan E, et al. Increasing bacterial resistance in pediatric acute conjunctivitis (1997–1998). Antimicrob Agents Chemother. 2000; 44(6): 1650–1654. PMID: 10817723
25. Dave SB, Toma HS, Kim SJ. Ophthalmic antibiotic use and multidrug-resistant Staphylococcus epidermidis: A controlled, longitudinal study. Ophthalmology. 2011; 118(10): 2035–2040. https://doi.org/10.1016/j.ophtha.2011.03.017 PMID: 21856006
26. Amato M, Pershing S, Walvick M, Tanaka S. Trends in ocular manifestations of methicillin-resistant Staphylococcus aureus (MRSA) in a northern California pediatric population. JAAPOS. 2013; 17: 243–247.

27. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003; 121: 1229–1233. https://doi.org/10.1001/archopht.121.9.1229 PMID: 12983604

28. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999; 106: 1319–1323. https://doi.org/10.1016/S0161-6420(99)00717-4 PMID: 10406614

29. Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006; 32: 515–518. https://doi.org/10.1016/j.jcrs.2005.12.108 PMID: 16631067

30. Chatterjee S, Agrawal D. Multi-drug resistant Pseudomonas aeruginosa keratitis and its effective treatment with topical colistimethate. Indian J Ophthalmol. 2016; 64: 153–157. https://doi.org/10.4103/0301-4738.179721 PMID: 27050354

31. Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in south Florida. Ophthalmology. 2008; 115(1): 51–56. https://doi.org/10.1016/j.ophtha.2007.03.076 PMID: 17572497

32. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008; 145(6):951–958. https://doi.org/10.1016/j.ajo.2008.10.025 PMID: 18374299

33. Asbell PA, Sahm DF. Longitudinal nationwide antimicrobial susceptibility surveillance in ocular isolates: results for Ocular TRUST 2. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting; April 28, 2008; San Diego, CA.

34. Asbell PA, Sanfilippo CM. Antibiotic resistance trends among ocular pathogens in the US—Cumulative results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. US Ophthalmic Review. 2017; 10(1): 35–38.

35. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 8th ed. Wayne, PA: Clinical & Laboratory Standards Institute; 2009. CLSI document M7-A8.

36. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 9th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. CLSI document M7-A9.

37. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. 10th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2015. CLSI document M7-A10.

38. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S19.

39. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S20.

40. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S21.

41. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S22.

42. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S23.

43. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S24.

44. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S25.

45. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Clinical & Laboratory Standards Institute; 2009–2016. CLSI document M100-S26.
46. Tukey J. Comparing individual means in the analysis of variance. Biometrics. 1949; 5(2): 99–114. PMID: 18151955

47. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955; 11(3): 375–386.

48. Moss JM, Sanislo SR, Ta CN. Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections. Ophthalmology. 2010; 117(11): 2141–2145. https://doi.org/10.1016/j. ophtha.2010.02.030 PMID: 20561687

49. Hsu HY, Lind JT, Tseng L, Miller D. Ocular flora and their antibiotic resistance patterns in the midwest: A prospective study of patients undergoing cataract surgery. Am J Ophthalmol. 2013; 155(1): 36–44. https://doi.org/10.1016/j.ajo.2012.06.024 PMID: 22995030

50. Karpecki P, Depaolis M, Hunter JA, White EM, Riger L, Brunner LS, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009; 31(3): 514–526. https://doi.org/10.1016/j.clinthera.2009.03.010 PMID: 19393842

51. Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009; 25(5): 1159–1169. https://doi.org/10.1185/03007990902837919 PMID: 19323612

52. McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009; 116: 1615–1623. https://doi.org/10.1016/j. ophtha.2009.05.014 PMID: 19643483

53. Malhotra R, Ackerman S, Gearinger LS, Allaire C. The safety of besifloxacin ophthalmic suspension 0.6% used three times daily for 7 days in the treatment of bacterial conjunctivitis. Drugs R D. 2013; 13: 243–252. https://doi.org/10.1007/s40268-013-0029-1 PMID: 24142473

54. DeLeon J, Silverstein BE, Allaire C, Gearinger LS, Bateman KM, Morris TW, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012; 32(5): 303–317. https://doi.org/10.2165/11632470-000000000-00000 PMID: 2240526

55. Morris TW, Gearinger LS, Usner DW, Paterno MR, DeCory HH, Comstock TL, et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes. Clin Ophthalmol. 2011; 5:1359–1367. https://doi.org/10.2147/OPTH.S23518 PMID: 22034555

56. Besivance (besifloxacin ophthalmic suspension) 0.6% Prescribing Information. Bausch & Lomb Incorporated, Bridgewater, NJ, June, 2016.

57. Olson R, Donnenfeld E, Bucci FA Jr, Price FW Jr, Raizman M, Soloman K, et al. Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery. Clin Ophthalmol. 2010; 4: 1505–1514. https://doi.org/10.2147/OPTH.S14333 PMID: 21191448

58. Kowalski RP, Yates KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ. An ophthalmologist’s guide to understanding antibiotic susceptibility and minimum Inhibitory concentration data. Ophthalmology. 2005; 112(11):1987. https://doi.org/10.1016/j.ophtha.2005.06.025 PMID: 16183128